PTC Therapeutics has withdrawn its resubmitted New Drug Application for Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy after receiving review feedback from the U.S. Food and Drug Administration.
According to the company, regulators indicated that the current clinical data package was unlikely to meet the agency’s standard of “substantial evidence of effectiveness,” a requirement for approval in the United States. Following this communication, PTC decided to formally withdraw the submission rather than continue the review process.
Chief Executive Officer Matthew B. Klein, M.D., said the company was disappointed with the outcome after more than two decades of work on the therapy. He emphasized the organization’s long-standing commitment to developing treatments for patients affected by nonsense mutation forms of Duchenne muscular dystrophy, a rare and fatal inherited condition primarily affecting boys.
Translarna is designed as a protein restoration therapy. It aims to enable cells to produce functional proteins when a “nonsense mutation” prematurely stops protein production. In Duchenne, the mutation prevents production of dystrophin — a critical structural protein necessary for muscle stability.
Duchenne muscular dystrophy causes progressive muscle weakness beginning in early childhood. Many patients lose the ability to walk around age 10 and later develop severe respiratory and cardiac complications, often leading to premature death in early adulthood.
PTC Therapeutics said it remains committed to advancing therapies for rare diseases and continues to develop a broader pipeline of treatments targeting serious unmet medical needs, though it did not specify immediate next steps for Translarna in the U.S. market.